- Home
- AYTU vs ADXN Comparison
AYTU vs ADXN Comparison
Compare AYTU & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- ADXN
- Stock Information
- Founded
- AYTU N/A
- ADXN 2002
- Country
- AYTU United States
- ADXN Switzerland
- Employees
- AYTU N/A
- ADXN N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- ADXN Health Care
- Exchange
- AYTU Nasdaq
- ADXN Nasdaq
- Market Cap
- AYTU 9.6M
- ADXN 10.1M
- IPO Year
- AYTU N/A
- ADXN N/A
- Fundamental
- Price
- AYTU $2.20
- ADXN $8.83
- Analyst Decision
- AYTU Strong Buy
- ADXN Strong Buy
- Analyst Count
- AYTU 2
- ADXN 1
- Target Price
- AYTU $10.00
- ADXN $30.00
- AVG Volume (30 Days)
- AYTU 207.1K
- ADXN 14.4K
- Earning Date
- AYTU 05-14-2025
- ADXN 08-11-2025
- Dividend Yield
- AYTU N/A
- ADXN N/A
- EPS Growth
- AYTU N/A
- ADXN N/A
- EPS
- AYTU N/A
- ADXN 0.10
- Revenue
- AYTU $81,659,000.00
- ADXN $278,508.00
- Revenue This Year
- AYTU N/A
- ADXN $86.57
- Revenue Next Year
- AYTU $8.68
- ADXN N/A
- P/E Ratio
- AYTU N/A
- ADXN $0.78
- Revenue Growth
- AYTU 0.41
- ADXN N/A
- 52 Week Low
- AYTU $0.95
- ADXN $6.51
- 52 Week High
- AYTU $2.88
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- AYTU 62.85
- ADXN 49.41
- Support Level
- AYTU $2.04
- ADXN $8.78
- Resistance Level
- AYTU $2.45
- ADXN $9.89
- Average True Range (ATR)
- AYTU 0.13
- ADXN 0.67
- MACD
- AYTU 0.01
- ADXN -0.03
- Stochastic Oscillator
- AYTU 68.00
- ADXN 43.01
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.